Sanofi vet Katherine Bowdish named CEO of PIC Therapeutics; As the world Terns: Liver disease biotech makes executive changes
Coronavirus pharma news roundup – 14/08/20
3 Healthcare Stocks Under $10 With Massive Upside Ahead
New tools catch and release molecules at the flip of a light switch
The pandemic has affected millions with other illnesses – here's how it affected a health professor's struggle with bulimia
JHU robotic system remotely controls ventilators in COVID-19 patient rooms
Oppenheimer: These 3 Penny Stocks Could Rally Over 100%
Digital depression therapy offers hope during COVID-19 pandemic
Eli Lilly, Innovent’s TYVYT Expanded Use Application Accepted In China
Mesoblast Tanks 35% Ahead Of FDA Meeting; Analyst Sees 85% Stock Upside
Potential Delay in Filing for Approval of Reata Pharmaceuticals’ FA Drug
Goldman Sachs: These 3 Stocks Are Poised to Soar by at Least 30%
Gilead Submits New Drug Application With FDA For Remdesivir
Eli Lilly, Innovent Deliver Encouraging Lung Cancer Data For Sintilimab
Amarin’s Vascepa To Take Part In Covid-19 Study In Adults With Heart Disease
3 Monster Growth Stocks That Can Rip Higher
Biogen Spikes 10% On FDA Fast Review For Potential Alzheimer Treatment
UPDATED: FDA hands out a quick OK for potential SMA blockbuster risdiplam, giving Genentech and Roche a chance to challenge rivals on the price
Parks and green spaces are important for our mental health – but we need to make sure that everyone can benefit
Top 200 Medicines Annual Report: Climbing Mount Humira
3 "Strong Buy" Healthcare Stocks Under $5 That Could See Outsized Gains
3 Healthcare Stocks Under $5 That Could See Outsized Gains
Delay in breast cancer operations appears non-life-threatening for early-stage disease
NTU develops peptide that makes drug-resistant bacteria sensitive to antibiotics again
Oppenheimer: These 3 “Strong Buy” Stocks Could Double, If Not More
Oppenheimer: These 3 “Strong Buy” Stocks Could See 120% Gains, If Not More
J.P. Morgan: These 2 Healthcare Stocks Are Must-Watch Names
GentiBio launches to develop engineered regulatory T cells for autoimmune and inflammatory diseases
Pharma’s rep soars on back of COVID-19, says FutureBrand
DBV craters on FDA’s peanut allergy immunotherapy rejection